

070

IMPACT OF PHARMACISTS IN ASSURING SAFE AND EFFECTIVE ATORVASTATIN TO ROSUVASTATIN CONVERSION (B1), Shanya Becha, Phillip Chiao, Shirley Chao. Veterans Affairs Medical Center, San Francisco, CA (shanya.becha@va.gov) IRB approval obtained.

The increased cost of atorvastatin therapy at the Veterans Affairs Medical Center in San Francisco has led to the implementation of a therapeutic interchange to rosuvastatin. This conversion has been estimated to result in a cost savings of approximately \$230,000. There are no prior studies that have evaluated therapeutic outcomes following formulary conversions. This retrospective outpatient medical chart review study will include 550 Veterans who were automatically converted from atorvastatin to rosuvastatin in July 2008. The primary outcome of this study will be determining the percentage of Veterans who remained at LDL goal post conversion from atorvastatin to rosuvastatin and pharmacist interventions. This study will identify patients who maintained their LDL goal post-conversion, enable pharmacists to make recommendations for patients who are no longer at their LDL goal, and monitor patient safety post-conversion by identifying possible side effects associated with the new drug. Pharmacists will be requesting lipid panels, liver function tests and serum creatinine if not available four months post conversion. Recommendations will also be made to providers for dose adjustments, medication change within the same or different therapeutic class, or

discontinuation of therapy. Preliminary data will be presented.